What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Australasian Leukaemia & Lymphoma Group - ALLG

Home
Australia
Melbourne, VIC
Australasian Leukaemia & Lymphoma Group - ALLG

For patients, this means an improved chance of cure, and better quality of life.

Since 1973 the ALLG has been pioneering life-changing blood cancer clinical trials, delivering innovative treatment options that transform the lives of those with blood cancer. The Australasian Leukaemia & Lymphoma Group (ALLG) is the only not-for-profit, collaborative clinical research group in Australia and New Zealand dedicated to finding new ways to treat blood cancers such as leukaemia, lymphoma, myeloma and myelodysplastic syndromes. The ALLG membership includes more than 1,000 doctors, nurses, scientists and support staff across Australia and New Zealand, all of whom are looking for ways to better treat blood cancers through clinical research. By conducting national and international collaborative clinical trials at sites across Australia and New Zealand, ALLG researchers are helping to make new and more effective treatments available to people suffering from blood cancers.

25/11/2025

ALLG's 2025 Annual Review highlights several key clinical trials that demonstrate our progress in delivering better treatments, better survival and better quality of life for people with blood cancers.

This year, our ALLG BM12 CAST trial demonstrated that a simpler, less toxic treatment regimen improves survival rates and reduces life-threatening complications like graft vs host disease (GVHD) in patients undergoing stem cell transplant for leukaemia. The results of this trial, published in the prestigious New England Journal of Medicine, are changing 40 years of standard clinical practice across Australia and New Zealand.

Our AMLM26 INTERCEPT trial is pioneering adaptive, precision treatment approaches to detect acute myeloid leukaemia (AML) earlier and provide access to new, innovative treatments to keep patients in remission longer for improved outcomes.

Our research is delivering better outcomes for people with blood cancer across Australia and New Zealand. Read more - https://tinyurl.com/4b8u6amv.

24/11/2025

Australian researchers have launched a new clinical trial offering hope for patients with transfusion dependent Myelodysplastic Syndromes (MDS), a form of blood cancer. The ALLG MDS05/D3 MESSAGE trial is exploring an innovative treatment combination designed to reduce the need for frequent blood transfusions, improve survival outcomes and enhance quality of life.

Learn more about this new trial and how it will help Australians with MDS - https://tinyurl.com/5n88ws98.

20/11/2025

From groundbreaking clinical trial research to real-world patient outcomes, our 2025 ALLG Annual Review celebrates the people and research driving change in blood cancer treatments and outcomes. Through ALLG's cutting-edge clinical trials, patients across Australia and New Zealand are accessing new, potentially better treatments that can save lives. To read more about ALLG’s work towards our mission of Better treatments…Better lives over 2025. Visit https://tinyurl.com/2mnucmvsto read more about our impact.

18/11/2025

It was an inspiring few days at the ALLG November Scientific Meeting, where ALLG members came together to share breakthroughs and shape the future of blood cancer trials. A highlight was keynote speaker Tiffany Boughtwood, the inaugural Genomics Commissioner from Genomics Australia, who discussed the role of genomics-informed healthcare and collaboration with Australia's 14 national Cooperative Cancer Trials Groups (CCTGs), including ALLG.

Thank you to all who contributed to the collaboration, innovation and momentum that continues to drive our mission forward for Better treatments…Better lives. To find out more, visit https://tinyurl.com/4b8u6amv.

13/11/2025

We're proud to officially launch the ALLG 2025 Annual Review at our Scientific Meeting today - allg.org.au.

This year's Annual Review highlights the life-changing work being delivered by our member researchers across Australia and New Zealand, delivering cutting-edge treatments to improve the outcomes and lives of people with blood cancers like leukaemia, lymphoma and myeloma.

Every ALLG trial is focused on delivering new, innovative treatments to people with blood cancer that aim to increase overall survival and quality of life. Our clinical trial research is only possible through the support of our community. As the only not-for-profit blood cancer clinical trial group in Australasia, we are committed to delivering clinical trials that create Better treatments…Better lives.

To find out more, or to support our blood cancer research, visit allg.org.au.

11/11/2025

ALLG’s November Scientific Meeting is underway - and we have officially kicked things off with the Haematology Education Day for members..

Focused on new clinical trial research, diagnostics and treatments for Acute Myeloid Leukaemia and Acute Lymphoblastic Leukaemia, the Education Day brings together expert blood cancer researchers from across Australia & NZ to drive meaningful progress for patients.

To find out more, or to support ALLG’s leading blood cancer research, visit allg.org.au.

10/11/2025

The ALLG November Scientific Meeting starts tomorrow with our Haematology Education Day. These biannual sessions are a key benefit to ALLG members, with blood cancer experts sharing the latest research, techniques and treatments to enable our haematologists to support patients across Australia and New Zealand.

Education is a key part of ALLG’s work, helping to drive blood cancer treatments forward that support better overall survival and quality of life. To find out more about ALLG’s blood cancer research, visit allg.org.au.

06/11/2025

Graft versus host disease (GVHD) is a serious complication of a stem cell transplant - a medical procedure that replaces cancer cells in your bone marrow with healthy donor stem cells. Stem cell transplants restore the body’s ability to produce new blood cells that help your immune system fight your cancer. GVHD can impact 1 in 3 stem cell transplant patients, with new donor cells attacking the host’s cells as unfamiliar cells that need to be destroyed. GVHD affects organs such as the mouth, eyes, lungs and bowels as well skin, liver, and the gastrointestinal tract. Depending on the severity, GVHD can sometimes be fatal.

Stephanie had already beaten leukaemia once before as a teenager when she received the devastating news in July 2020 that her leukaemia was back, and she needed a stem cell transplant. She says, “While my worst fears were confirmed with my relapse, the looming threat of GVHD made everything worse. It coloured every decision I made.”

Hope came with the opportunity to participate in a clinical trial. ALLG’s BM12 CAST trial, led by Professor David Curtis, was testing a new treatment combination aimed at significantly reducing the risk of developing GVHD for patients.

Stephanie shares what being part of the trial meant to her: “The trial gave me hope – it made me feel like I was part of something bigger and like I was doing something not just for myself but for people like me in the future.” Thanks to the BM12 trial’s new treatment, Stephanie remains healthy and free of her leukaemia and GVHD.

As Australasia’s only not-for-profit blood cancer clinical trial group, ALLG and our researcher members are creating better treatments and better lives for people with blood cancers like leukaemia, lymphoma and myeloma – people just like Stephanie.

By donating to ALLG, you are supporting our leading researchers to deliver cutting edge treatment options and change the trajectory of blood cancer research in Australia and New Zealand: https://www.allg.org.au/make-a-donation/.

03/11/2025

The ALLG's November Scientific Meeting is just around the corner - 11-14 at the Park Hyatt, Melbourne. These events unite expert clinicians and our members to explore new innovative ideas and treatments in blood cancer. They are a vital to sharing knowledge of global emerging trends that have the potential to shape patient care.

ALLG is a not-for-profit organisation and relies on the support of people like you - who help drive research that has a profound impact on patients and families. To learn more and get involved, visit allg.org.au.

30/10/2025

Want to take part in a once in a lifetime event and make a difference to the future of blood cancer research? Now is your chance! ALLG is thrilled to announce that we have five charity superstar places at the 2026 Sydney Marathon, reserved specially for you – our superstar community! Follow the link - https://sm26.grassrootz.com/allg to sign up now to become a champion for all those impacted by blood cancers like leukaemia, lymphoma, and myeloma.

This is your opportunity to take part in the only World Marathon Major in the southern hemisphere and raise funds for ALLG’s vital clinical trial research into new, better treatments for blood cancers. The Sydney Marathon is now completely sold out – with charity superstar places the only way to run this amazing marathon in 2026!

Whether you’re chasing a new personal best or just looking to be part of something bigger, the Sydney Marathon 2026 is your chance to make every step count. There are only FIVE spots so hurry and sign up NOW to be part of this iconic event and become a superstar for blood cancer research in Australia and New Zealand.

Click here for your chance to be a superstar: https://sm26.grassrootz.com/allg or read more at https://tinyurl.com/53ww5ua9.

29/10/2025

ALLG is delighted to introduce our 2026 ALLG HSANZ Clinical Trials Fellow – Dr Safia Belbachir from Fiona Stanley Hospital.

The ALLG Fellowship program is vital to support the next generation of blood cancer researchers and clinical triallists to drive better treatments and outcomes for people with blood cancer. Fellows receive funding to undertake a 12-month research project into blood cancers through ALLG’s clinical trial research portfolio.

Dr Belbachir’s research project is titled, "An investigator-initiated, translational study evaluating pharmacogenomic predictors of cyclophosphamide-related toxicity and efficacy in allogeneic stem cell transplant recipients receiving post-transplant cyclophosphamide (PTCY). "

This research will investigate new ways to prevent graft-versus-host-disease (GVHD) in allogeneic stem cell transplantation by researching how genetic variations (pharmacogenomics) influence the effectiveness of key treatment post-transplant cyclophosphamide. Dr Belbachir’s research will help to guide personalised dosing and treatment selection that may lead to new, precision medicine approaches for stem cell transplant patients across Australia.

We are excited to share more about Dr Belbachir’s research throughout her 2026 Fellowship. To read more about our 2026 Fellow, visit https://tinyurl.com/y79ue84k.

If you would like to know more about the ALLG Fellowship Program and our recipients, or to make a donation to support this program, visit www.allg.org.au/support-us/our-campaigns.

27/10/2025

ALLG congratulates all our members who have had ALLG clinical trial abstracts accepted at the Blood 2025 Conference in Perth, Australia.

Our members are the driving force behind our leading clinical trials for people with leukaemia, lymphoma, myeloma and other blood cancers. Accepted research abstracts represent the most novel research in the field across Australasia and will be presented to over 1,200 haematology specialists attending Blood 2025.

This success highlights the commitment and dedication of our member researchers to ALLG’s mission of Better treatments…Better lives.

To discover more about ALLG’s research and the impact of our clinical trials for people with blood cancer, visit allg.org.au.

Address

Ground Floor, 35 Elizabeth Street
Melbourne, VIC
3121

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Website

https://www.allg.org.au/support-us/make-a-donation/

Alerts

Be the first to know and let us send you an email when Australasian Leukaemia & Lymphoma Group - ALLG posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Australasian Leukaemia & Lymphoma Group - ALLG:

Shortcuts

Want your practice to be the top-listed Clinic in Melbourne?

Our Story

The Australasian Leukaemia & Lymphoma Group (ALLG) is the only not-for-profit, investigator run clinical research group in Australia and New Zealand dedicated to finding new ways to treat blood cancers such as leukaemia, lymphoma, myeloma and myelodysplastic syndromes. The ALLG membership includes more than 750 doctors, nurses, scientists and professional staff across Australia and New Zealand, all of whom are looking for ways to better treat blood cancers through clinical research. By conducting national and international collaborative clinical trials at sites across Australia and New Zealand, ALLG researchers are helping to make new and more effective treatments available to people suffering from blood cancers. For patients, this means an improved chance of cure, and better quality of life.